GGO Vergunningendatabase

Zoekcriteria
Zoekresultaat
C/NL/06/01_001 Suntory Flowers Limited Application for renewal of consent for marketing approval under Directive 2001/18/EC (Event FLORIGENE®Moonaqua™(FLO-4Ø689-6)) 09-11-2018 Vergunning verleend
IM-MV 18-013_000 UMCG A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-seropositive Donors (D+) Vergunning verleend
IM-MV 18-014_000 LUMC RAG1‐SCID and RAG2‐SCID CD34+ gene therapy using 3rd generation self‐inactivating (SIN)‐lentiviral vector Ontwerpbesluit genomen
IM-MV 19-002_000 Universitair Medisch Centrum Utrecht Clinical testing of JNJ-68284528, composed of autologous T cells genetically modified with a lentiviral vector (LVV) to express a chimeric antigen receptor (CAR) that, upon reinfusion into the patient, recognize and kill B-cell maturation antigen (BCMA)-expressing tumour cells 02-07-2019 Vergunning verleend
IM-MV 19-003_000 Erasmus MC An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma and further clinical studies with VXM01 in patients with solid malignancies 05-06-2019 Vergunning verleend
IM-MV 19-004_000 Erasmus MC Clinical testing of MC2 TCR T cells, an autologous cellular immunotherapy composed of autologous T cells genetically modified ex vivo to express a T cell receptor (TCR) that, upon reinfusion into the patient, recognize and kill MAGE-C2 (MC2)-expressing tumor cells Ontwerpbesluit genomen
IM-MV 19-005_000 Erasmus MC Phase III study testing bb2121, consisting of autologous T lymphocytes ex-vivo transduced by a replication-defective lentiviral vector to express anti-BCMA chimeric antigen receptors (CAR) to target tumor cells expressing the human B cell maturation antigen (BCMA), in patients with relapsed and refractory multiple myeloma (RRMM) Ontwerpbesluit genomen
IM-MV 19-007_000 Het Nederlands Kanker Instituut An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma and further clinical studies with VXM01 in patients with solid malignancies Ontwerpbesluit genomen